Publications

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-Vmp) Versus Bortezomib, Melphalan, and Prednisone (Vmp) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (Ndmm): Updated Analysis of the Phase 3 Alcyone Study

AuthID
P-00Y-1RF

Author(s)

Mateos, MV

San-Miguel, J

Cavo, M

Creixenti, JB

Suzuki, K

Jakubowiak, A

Knop, S

Doyen, C

Lucio, P

Nagy, Z

[+5]·

Shelekhova, T

Yoon, SS

Iosava, G

Fujisaki, T

Garg, M

Pei, HL

Krevvata, M

Carson, R

Borgsten, F

Dimopoulos, MA

View all authors

Document Type

Abstract

Year published

2022

Published

in BLOOD, ISSN: 0006-4971

Volume: 140, Pages: 10157-10159 (3)

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1182/blood-2022-163347

Wos: WOS:000893230303073

Source Identifiers

ISSN: 0006-4971

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

All authors

Show entries

Search:

Name Order	Name	Name Order	Name	Name Order	Name
1	Mateos, MV;	2	San-Miguel, J;	3	Cavo, M;
4	Creixenti, JB;	5	Suzuki, K;	6	Jakubowiak, A;
7	Knop, S;	8	Doyen, C;	9	Lucio, P;
10	Nagy, Z;	11	Pour, L;	12	Grosicki, S;
13	Crepaldi, AH;	14	Liberati, AM;	15	Campbell, P;
16	Shelekhova, T;	17	Yoon, SS;	18	Iosava, G;
19	Fujisaki, T;	20	Garg, M;	21	Pei, HL;
22	Krevvata, M;	23	Carson, R;	24	Borgsten, F;
25	Dimopoulos, MA;

Showing 1 to 9 of 9 entries

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-Vmp) Versus Bortezomib, Melphalan, and Prednisone (Vmp) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (Ndmm): Updated Analysis of the Phase 3 Alcyone Study

Useful Links

Get Help

Federated Authentication (Click on the image)

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-Vmp) Versus Bortezomib, Melphalan, and Prednisone (Vmp) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (Ndmm): Updated Analysis of the Phase 3 Alcyone Study

Useful Links

Get Help